评价脓毒症免疫抑制生物标志物的4个标准  

Four criteria for evaluating biomarkers of immunosuppression in sepsis

作　　者：裴飞[1] 吴健锋[1] Pei Fei;Wu Jianfeng(Department of Critical Care Medicine,the First Affiliated Hospital,Sun Yat-sen University,Guangdong Clinical Research Center for Critical Care Medicine,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院重症医学科、广东省重症医学临床研究中心,广州510080

出　　处：《中华检验医学杂志》2023年第10期992-996,共5页Chinese Journal of Laboratory Medicine

基　　金：国家自然科学基金(82272186, 82002076);广东省重点领域研发计划(2023B1111020002);广东省自然科学基金(2016A030313269);中山大学5010研究(2019002)。

摘　　要：免疫抑制是造成脓毒症患者不良预后的关键环节。免疫状态评估是识别免疫抑制患者和明确免疫治疗时机的先决条件。探索脓毒症免疫状态评估的生物标志物成为目前的研究热点。然而, 近年来大量生物标志物的出现却给临床医生造成选择的困扰。脓毒症免疫抑制理想生物标志物有4个标准。Immunosuppression is a key element of poor prognosis in patients with sepsis.The immune status assessment is a prerequisite for identifying immunosuppressed patients and clarifying the timing of immunotherapy.Exploring biomarkers for immune status assessment in sepsis has become a current hot spot.However,the availability of a large number of biomarkers in recent years has presented clinicians with a selection problem.There is four criteria for ideal biomarkers of sepsis immunosuppression for the screening of potential biomarkers of sepsis immunosuppression.

关 键 词：脓毒症 免疫监测 免疫抑制 单核细胞HLA-DR 淋巴细胞数目 

分 类 号：R459.7[医药卫生—急诊医学]